An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs KN-046 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Alphamab
- 21 Oct 2019 Planned End Date has been changed to 1 Apr 2020.
- 21 Oct 2019 Status has been changed to active, no longer recruiting.
- 04 Jun 2019 Interim results (Data cut off 13 Dec 2018, n=10) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History